Alteplase Other names: Tissue-type plasminogen activator precursor tPA t-PA t-plasminogen activator

Therapeutic indications

Alteplase is indicated for:

Acute massive pulmonary embolism with haemodynamic instability

Population group: only adults (18 years old or older)

Alteplase is indicated for the thrombolytic treatment in acute massive pulmonary embolism with haemodynamic instability. The diagnosis should be confirmed whenever possible by objective means such as pulmonary angiography or non-invasive procedures such as lung scanning. There is no evidence for positive effects on mortality and late morbidity related to pulmonary embolism.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute myocardial infarction

Population group: only adults (18 years old or older)

Alteplase is indicated for thrombolytic treatment in acute myocardial infarction.

90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h after symptom onset.

3 h dose regimen: for patients in whom treatment can be started between 6-12 h after symptom onset provided that the diagnosis has been clearly confirmed.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute ischaemic stroke

Population group: only adults (18 - 65 years old)

Alteplase is indicated for the fibrinolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Alteplase is contraindicated in the following cases:

Haemorrhage

Bleeding

Severe uncontrolled arterial hypertension

Hypertension

Bacterial endocarditis, pericarditis

at least one of
Bacterial endocarditis
Pericarditis

ฮ‘cute pancreatitis

Acute pancreatitis

Neoplasm with increased bleeding risk

Neoplasms

Ulcerative gastrointestinal disease, oesophageal varices, arterial-aneurysm, arterial/venous malformations

at least one of
Gastrointestinal ulcer
Esophageal varices
Arterial aneurysm

Severe liver disease, hepatic failure, cirrhosis, portal hypertension, active hepatitis

at least one of
Hepatic failure stage IV
Inflammatory disorder of liver
Portal hypertension

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL) 2020: CATHFLO ACTIVASE Powder for solution for injection
Summary of Product Characteristics (SPC) 2018: ACTILYSE Powder and solvent for solution
< Previous: Overview
Next: Precautions >

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈